

Date: October 6, 2020

The Secretary,
Listing Department,
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
C/1 G Block, Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051
(Scrip Code: THYROCARE)

The Secretary,
Listing Department,
BSE Limited
Phiroze Jeejeeboy Towers
Dalal Street,
Mumbai- 400 001
(Scrip Code: 539871)

Dear Sir/Madam,

Sub: Intimation under Regulation No. 30 & 36 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

We would like to make the following announcements and business update for the knowledge of our shareholders, investors, and general public:

1. Thyrocare has done more than 4.00 Lakh COVID-19 RT-PCR tests and more than 3.20 Lakh COVID antibody tests as on 30.09.2020
2. While we have enhanced the capacity to do RT-PCR tests, 400 per hour, we have got approvals for our new facility at Gurgaon, Delhi by NABL. It also has been built with an ability to do 400 tests per hour.
3. Anticipating more workloads in quarters to come, we are also creating facilities with COVID testing facilities in Bangalore and Kolkata as well, to meet the demand that may arise due to prolonged pandemic. With non COVID tests coming back to track, we anticipate a need for more capacity and facilities.
4. Q2 of FY 21 has witnessed a motivating numbers and increased turnover of COVID PCR and COVID Antibody testing, and the aggregate revenue for the quarter ended 30 September 2020, has increased by about 37% compared to Q2 of FY 20. The low revenue in Q1 of FY 21 has bounced back in Q2 of FY 21 with a very healthy growth of 171% over trailing quarter.



Thyrocare Technologies Limited

5. Last 200 days have been really tough for the entire world, country, life, business and even for company but we wish to place on records, that our team withstood and used the pains as opportunities. While we did the best in Quality, Cost and Speed even in COVID testing, the Company had to face many surprising and shocking blocks in business by those who did not understand the virus and its characteristics of becoming positive to negative or vice versa, by many of government functionaries, municipal commissioners. We were reprimanded by a few without even issuing a Show Cause Notice or without even giving a proper opportunity of being heard. We are happy to announce that on the direction of the Hon'ble Bombay High Court, all the orders passed discretionally by these administrators are now withdrawn, and we are allowed to operate in all parts of the country, without which hindrance, our Q2 results could have been much better.

The quarterly financial statements for the quarter ended 30 September 2020 are under review by our statutory auditors and we will file our detailed financial release post approval by the Audit Committee and the Board, sooner. Since convening physical general meeting is rendered impossible on account of pandemic Covid-19, we are unable to communicate with our shareholders in an effective manner, as also meet their queries.

Therefore, in terms of the Clauses 30 & 36 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we hereby apprise you and all our shareholders / stakeholders of the above material developments having a bearing on our performance / operations / finance, which information we consider as 'price sensitive' concerning our listed securities.

We request you to kindly take on record the above. We are also posting this intimation on our web site.

For Thyrocare Technologies Limited

Ramjee Dorai
Company Secretary & Compliance Officer



Thyrocare Technologies Limited

📍 D-37/1, TTC MIDC, Turbhe, Navi Mumbai - 400 703, India ☎ 022- 3090 0000 / 4125 2525

✉ enquiry@thyrocare.com 🌐 www.thyrocare.com

(CIN : L85110MH2000PLC123882)